Patents Assigned to LEAD PHARMA CEL MODELS IP B.V.
  • Patent number: 9738600
    Abstract: A11-14 are N or CR11-14, respectively, maximum two of the four positions A simultaneously N; R1 is C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, (di)C(1-6)alkylamino, (di)C(3-6)cycloalkylamino or (di)(C(3-6)cycloalkylC(1-3)alkyl)amino, all alkyl and cycloalkyl group carbon atoms optionally substituted with F and F or methyl, respectively; R2 and R3 independently H, F, methyl, ethyl, hydroxy, methoxy or R2 and R3 together is carbonyl, all present alkyl groups optionally substituted with F; R4 is H or C(1-6)alkyl; R5 is H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl, all groups optionally substituted with F, Cl, C(1-2)alkyl, C(1-2)alkoxy or cyano; the sulfonyl group with R1 represented by one of R7-9; the remaining R6-14 are independently H, halogen, C(1-3)alkoxy, (di)C(1-3)alkylamino or C(1-6)alkyl, all alkyl gr
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: August 22, 2017
    Assignee: LEAD PHARMA CEL MODELS IP B.V.
    Inventors: Joseph Maria Gerardus Barbara Cals, Sander Bernardus Nabuurs
  • Publication number: 20160304448
    Abstract: A11-14 are N or CR11-14, respectively, maximum two of the four positions A simultaneously N; R1 is C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, (di)C(1-6)alkylamino, (di)C(3-6)cycloalkylamino or (di)(C(3-6)cycloalkylC(1-3)alkyl)amino, all alkyl and cycloalkyl group carbon atoms optionally substituted with F and F or methyl, respectively; R2 and R3 independently H, F, methyl, ethyl, hydroxy, methoxy or R2 and R3 together is carbonyl, all present alkyl groups optionally substituted with F; R4 is H or C(1-6)alkyl; R5 is H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl, all groups optionally substituted with F, Cl, C(1-2)alkyl, C(1-2)alkoxy or cyano; the sulfonyl group with R1 represented by one of R7-9; the remaining R6-14 are independently H, halogen, C(1-3)alkoxy, (di)C(1-3)alkylamino or C(1-6)alkyl, all alkyl gr
    Type: Application
    Filed: December 3, 2014
    Publication date: October 20, 2016
    Applicant: LEAD PHARMA CEL MODELS IP B.V.
    Inventors: Joseph Maria Gerardus Barbara Cals, Sander Bernardus Nabuurs
  • Publication number: 20100203021
    Abstract: The present invention relates to cardiomyocyte progenitor cells (CMPCs), to methods for their isolation and to the use of this CMPCs for the provision of cardiomyocytes, by way of differentiating the obtained CMPCs with a demethylating agent. The present invention also relates to pharmaceuticals compositions comprising cardiomyocytes for use in a cardiomyocyte replacement therapy and/or for the treatment in myocardial infarctation or for ameliorating the effects of myocardial infarctation.
    Type: Application
    Filed: January 9, 2008
    Publication date: August 12, 2010
    Applicant: LEAD PHARMA CEL MODELS IP B.V.
    Inventors: Marie Jose Goumans, Pieter Doevendans